Literature DB >> 11536329

Antibodies directed against rubella virus induce demyelination in aggregating rat brain cell cultures.

C Besson Duvanel1, P Honegger, J M Matthieu.   

Abstract

To link the presence of intrathecal virus-specific oligoclonal immunoglobulin G (IgG) in multiple sclerosis patients to a demyelinating activity, aggregating rat brain cell cultures were treated with antibodies directed against two viruses, namely, rubella (RV) and hepatitis B (HB). Anti-RV antibodies in the presence of complement decreased myelin basic protein concentrations in a dose-dependent manner, whereas anti-HB antibodies had no effect. A similar but less pronounced effect was observed on the enzymatic activity of 2',3'-cyclic nucleotide 3'-phosphohydrolase, which is enriched in noncompact membranes of oligodendrocytes. These effects were comparable to those in cultures treated with antibodies directed against myelin oligodendrocyte glycoprotein (MOG), previously found to be myelinotoxic both in vitro and in vivo. Sequence homologies were found between structural glycoprotein E(2) of RV and MOG, suggesting that demyelination was due to molecular mimicry. To support the hypothesis that demyelination was caused by anti-RV IgG that recognized an MOG epitope, we found that anti-RV antibodies depleted MOG in a dose-dependent manner. Further evidence came from the demonstration that anti-RV and anti-MOG IgG colocalized on oligodendrocyte processes and that both revealed by Western blot a 28 kDa protein in CNS myelin, a molecular weight corresponding to MOG. These findings suggest that a virus such as RV exhibiting molecular mimicry with MOG can trigger an autoimmune demyelination. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536329     DOI: 10.1002/jnr.1173

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

1.  Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus.

Authors:  Haolong Cong; Yue Jiang; Po Tien
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

2.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

Review 3.  Molecular and Structural Insights into the Life Cycle of Rubella Virus.

Authors:  Pratyush Kumar Das; Margaret Kielian
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

Review 4.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

Review 5.  Virus entry: old viruses, new receptors.

Authors:  Marija Backovic; Felix A Rey
Journal:  Curr Opin Virol       Date:  2012-01-02       Impact factor: 7.090

6.  Zika Virus: A New Animal Model for an Arbovirus.

Authors:  M Javad Aman; Fatah Kashanchi
Journal:  PLoS Negl Trop Dis       Date:  2016-05-05

7.  The Relationship between Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and the Rubella Virus.

Authors:  Seok Jin Choi; Dan A Oh; Woochang Chun; Sung Min Kim
Journal:  J Clin Neurol       Date:  2018-10       Impact factor: 3.077

Review 8.  Molecular mimicry in multiple sclerosis.

Authors:  Jane E Libbey; Lori L McCoy; Robert S Fujinami
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.